Company Profile

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâ€™s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Employees

200

Sector

Biotechnology & Medical Research

More about the company

24-05-23	Pear Therapeutics, Inc. Went Out of Business	CI
24-05-08	Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc.	CI
24-03-22	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
24-03-03	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI
24-02-11	Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
23-12-12	Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
23-08-04	First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
23-07-20	First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	CI
23-05-23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
23-05-23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
23-05-21	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
23-05-20	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
23-05-19	Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	CI

23-03-20	Credit Suisse Downgrades Pear Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	MT
23-03-20	TD Cowen Downgrades Pear Therapeutics to Market Perform From Outperform	MT
23-03-20	Chardan Downgrades Pear Therapeutics to Neutral From Buy, Citing Cash Constraints, Withdraws Price Target	MT
22-11-16	Citigroup Adjusts Price Target on Pear Therapeutics to $5 From $7, Maintains Buy Rating	MT
22-11-15	Credit Suisse Lowers Pear Therapeutics' PT to $7 From $9, Updates Model After Q3 Actuals, Management Guidance; Keeps Outperform Rating	MT

23-04-10	PEAR THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-04-10	PEAR THERAPEUTICS FILES FOR CHAPTER 11 AND WILL SEEK TO SELL ASSETS THROUGH SALES PROCESS	AQ
23-04-07	PEAR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-04-07	Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process	BU
23-03-31	PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ

Manager	Title	Age	Since
Christopher Guiffre CEO	Chief Executive Officer	58	2023-04-05
Ilya Gluhovsky CTO	Chief Tech/Sci/R&D Officer	-	-
Maria Sullivan CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Corey McCann BRD	Director/Board Member	47	2021-11-30
Shiva Rajaraman BRD	Director/Board Member	52	2022-06-13

Pear Therapeutics, Inc. Stock

Stocks

PEAR

US7047231052

Biotechnology & Medical Research

Latest news : Pear Therapeutics, Inc.

Analysts' recommendations: Pear Therapeutics, Inc.

Press Releases: Pear Therapeutics, Inc.

News in other languages: Pear Therapeutics, Inc.

Managers and Directors: Pear Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-04-09	5AM Venture Management LLC	Sell	Company	16,544,113	11.8148%
23-02-14	Shiva Rajaraman	Free	Director	52,380	0.0374%
23-02-14	Alison Bauerlein	Free	Director	71,428	0.0510%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEAR THERAPEUTICS, INC.	-.--%	-.--%	-	-	142
LONZA GROUP AG	+0.58%	+2.06%	+3.90%	+9.78%	50.73B
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+391.53%	+593.69%	39.73B
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+27.67%	-5.10%	34.69B
BEONE MEDICINES AG	-1.36%	+0.35%	+19.34%	+55.53%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+31.73%	26.76B
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	16.8B
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+66.38%	+122.57%	15.37B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.80%	+16.17%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+11.43%	-31.02%	12.85B
Average	-0.40%	-0.83%	+67.13%	+99.17%	27.1B
Weighted average by Cap.	-0.48%	-0.23%	+82.75%	+124.64%